Parathyroid Carcinoma has always been among the rarest cancers we have seen in the human race. On this point the medical approach to cancer is very much underestimated. It was described over 100 years ago in 1909 by de Quervain, since that time, fewer than 1,000 patients have been reported iBecause of the rarity of this malignancy, a standardized TNM staging algorithm is not universally accepted. Primary index tumor size and nodal involvement do not reliably correlate with recurrence-free survival or overall survival in the literature. Although it finds a very hard time with the proper management.
Parathyroid carcinoma is a rare malignancy representing less than 0.005% of all cancers and less than 1% of all parathyroid disorders.The 10-year mortality rate for parathyroid carcinoma is 33.2%, with cancer-related mortality of 12.4%. These nonfunctional carcinomas account for less than 10% of all parathyroid carcinomas.Lymph node metastases may occur in 6%-30% of patients with parathyroid carcinoma. For patients with parathyroid carcinoma, 10%-30% will have metastatic disease at presentation, most commonly to the lung, bone, or liver.
Being a rare malignancy this type of cancer does need a very proper prognosis for developing further mode of action.
https://ascopubs.org/doi/full/10.1200/JOP.19.00540
